Telix Releases Results for the Year Ended 31 December 2021 and 2021 Annual Report
Telix Pharmaceuticals Limited Releases Full-Year 2021 Results and 2021 Annual…
Read moreNews & Views
Telix Enters Commercial Distribution Agreement for Illuccix® in Australia
Telix announces a commercial distribution agreement with Global Medical Solutions Australia (GMSA), for Illuccix® in the Australian…
Read more
Telix and SHINE partner for Lutetium-177 Supply
Telix announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for…
Read more
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
News,
Telix announces a global clinical supply agreement with Eckert & Ziegler for…
Read more
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
Telix and Kanazawa University announce that the Phase I clinical study of TLX591-CDx for prostate cancer imaging in Japanese patients has met its…
Read more
Darren Smith Joins Telix as Deputy Group Chief Financial Officer
Telix is pleased to announce that Darren Smith has joined the Company as Deputy Group Chief Financial Officer….
Read more
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
Telix signs a commercial distribution agreement with BIOKOSMOS for prostate cancer investigational imaging product Illuccix® in Greek and Cypriot…
Read more
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
Telix announces that the first patient has been dosed in the Company’s PSMA-targeting ‘ProstACT’ therapeutic…
Read more
Telix Completes A$175 Million Placement and Launches A$25 Million SPP
Telix announces a successful $175 million institutional placement and launches Share Purchase Plan to raise up to $25…
Read more
Activities Report and Appendix 4C for December 2021 Quarter
Telix provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December…
Read more